Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341952 · ClinicalTrials.gov registry record
Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
A clinical trial of Non-Hodgkin's Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,378
- Enrollment target
- 4
- Study locations
NCT00341952 is a study of Non-Hodgkin's Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,378 participants, above the 184-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (1192% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT00341952, a study of Non-Hodgkin's Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,378 participants
- Enrollment target
- 4
- Study locations
Study Summary
Non-Hodgkin's lymphoma (NHL) incidence rates have risen three percent per year in the U.S. for four decades. Mortality from NHL has risen 1.6 percent, compared with 0.2 percent for all cancers combined. This epidemic curve appears in both sexes and around the world, suggesting the possibility of an etiologic agent increasing in prevalence in the general environment. Recent research has identified several possible candidates including pesticides, other organochlorines, drinking water nitrates, and sunlight. There is an urgent need to evaluate whether these common exposures are contributing to the rapid rise in NHL, and to investigate other hypothesized risk factors such as viruses, medical conditions, hair dye use, and genetic factors. The purpose of this study is to examine the contribution to NHL risk of these important environmental, occupational, viral, medical, and personal exposures, and to pursue important leads emerging from on-going NHL research. This multidisciplinary, population-based case-control study will involve personal interviews to collect information on demographics, residential history, pesticide use, and occupational exposures; self-administered questionnaires to collect information on diet, family and medical history, and other exposures; tap water and carpet dust sampling to collect information on nitrate and pesticide exposures; and blood sampling for measurements of compounds in the serum, antibodies to viruses, and examination of genetic polymorphisms.
Conditions Studied
Study Locations (4)
California
- University of Southern California - Los Angeles
Iowa
- University of Iowa - Iowa City
Michigan
- Wayne State University Hutzel Hospital - Detroit
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,378 participants |
| Start Date | 1998-04-15 |
| Est. Completion | 2007-04-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00341952
The ClinicalTrials.gov registry entry for NCT00341952 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,378 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (1192% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 0 interventions.
NCT00341952 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Iowa, Michigan.
Frequently Asked Questions
What is clinical trial NCT00341952 about?
NCT00341952 is a clinical study titled "Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma". Non-Hodgkin's lymphoma (NHL) incidence rates have risen three percent per year in the U.S. for four decades. Mortality from NHL has risen 1.6 percent, compared with 0.2 percent for all cancers combined. This epidemic curve appears in both sexes and around the world, suggesting the possibility of an ...
What is the current status of trial NCT00341952?
This trial is currently completed. The enrollment target is 2,378 participants. The study started on 1998-04-15. Estimated completion is 2007-04-17.
What conditions does trial NCT00341952 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
Who is sponsoring clinical trial NCT00341952?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00341952 being conducted?
This trial has 4 study locations across California, Iowa, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
RECRUITING
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
RECRUITING
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.